Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alectinib - Roche

Next Previous
X
Search
Drug Profile

Alectinib - Roche

Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802

Latest Information Update: 08 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; National Hospital Organization Nagoya Medical Center; Roche; Seoul National University Hospital; University College London
  • Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; Anaplastic large cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Registered Anaplastic large cell lymphoma
  • Phase II Solid tumours
  • Phase I/II Brain cancer; Thyroid cancer

Most Recent Events

  • 02 Oct 2024 Roche plans a phase II HORIZON 2 trial for Non-small cell lung cancer (Late-stage disease, neoadjuvant therapy, combination therapy) in Chile (PO) (NCT06624059)
  • 27 Jun 2024 Preregistration for Non-small cell lung cancer (Adjuvant therapy) in Canada (PO) prior to June 2024
  • 27 Jun 2024 Registered for Non-small cell lung cancer (Adjuvant therapy) in Canada (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top